KCCure is a patient-driven, evidence-based advocacy organization. KCCure research grants are designed to fund priorities driven by patients in our communities and fill gaps in care uncovered through our patient centered research program.
The KCCure Chromophobe Grant is a patient-driven, peer-reviewed research award aimed at prioritizing innovative scientific research in chromophobe renal cell carcinoma.
Chromophobe RCC is a rare subtype of kidney cancer accounting for roughly 5 percent of RCC tumors. When discovered early, this histological type is less likely to spread to other parts of the body. However, once the disease becomes metastatic, survival rates are poor.
Over the past decade, more than seventeen new treatments have been approved by the FDA to treat kidney cancer. However, these treatments have all been established in clear cell RCC patients, the most common form of the disease. No treatments have been identified for chromophobe RCC.
The Chromophobe RCC Grant provides $50,000 for one year of research, paid in a single installment. Requests for proposals are sent out to centers across the United States. To ensure scientific merit, proposals are judged by a review panel composed of physicians and scientists with applicable expertise. High priority is given to project innovation and potential clinical impact. The winning proposal is selected by a programmatic panel made up of patients and caregivers from the Chromophobe RCC community.
The program was launched in 2021, with the first award announced in March 2022. The application period for new proposals will open again in November 2022.
Donations to support this program can be made here.